"SANKYO" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonPatient Deaths Put Merck, Daiichi Sankyo’s Antibody-Drug Conjugate on Hold - BioSpace
Patient Deaths Put Merck, Daiichi Sankyo’s Antibody-Drug Conjugate on Hold BioSpace
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Tr...
Patient deaths prompt partial hold for Daiichi-Merck's global phase 3 ADC program - Fierce Biotech
Patient deaths prompt partial hold for Daiichi-Merck's global phase 3 ADC program Fierce Biotech
Lunit and Daiichi Sankyo Form Collaboration to Advance Research and Discovery for AI-Driven Bioma...
Lunit, Daiichi Sankyo collaborate on AI pathology in oncology research - FirstWord Pharma
Lunit, Daiichi Sankyo collaborate on AI pathology in oncology research FirstWord Pharma
Lunit links up with Daiichi Sankyo in oncology - The Pharma Letter
Lunit links up with Daiichi Sankyo in oncology The Pharma Letter
Lung toxicity deaths halt ifinatamab | ApexOnco - Clinical Trials news and analysis - Oncology Pi...
Lung toxicity deaths halt ifinatamab | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Here's Why Sankyo (TSE:6417) Has Caught The Eye Of Investors - simplywall.st
Here's Why Sankyo (TSE:6417) Has Caught The Eye Of Investors simplywall.st
AZ, Daiichi score with FDA nod for Enhertu combo in 1st-line breast cancer - Fierce Pharma
AZ, Daiichi score with FDA nod for Enhertu combo in 1st-line breast cancer Fierce Pharma
AstraZeneca, Daiichi Sankyo ADC Enhertu Moves Up to First-Line Use in Breast Cancer - MedCity News
AstraZeneca, Daiichi Sankyo ADC Enhertu Moves Up to First-Line Use in Breast Cancer MedCity News
Enabling data-driven business with global digital transformation platform - DXC Technology
Enabling data-driven business with global digital transformation platform DXC Technology
Lunit, Daiichi Sankyo to partner on AI biomarker, oncology research - AuntMinnie
Lunit, Daiichi Sankyo to partner on AI biomarker, oncology research AuntMinnie
AstraZeneca, Daiichi Sankyo's Enhertu Regimen Greenlit as First-line Breast Cancer Treatment in U...
AstraZeneca, Daiichi Sankyo's Enhertu Regimen Greenlit as First-line Breast Cancer Treatment in US Yahoo Finance UK
Merck and Daiichi Sankyo Suspend Development of DXd-Based Cancer Drug After Patient Deaths Linked...
Merck and Daiichi Sankyo Suspend Development of DXd-Based Cancer Drug After Patient Deaths Linked to Interstitial Lung Disease geneonline.com
Lunit and Daiichi Sankyo Partner to Accelerate Cancer Biomarker Discovery with AI - HIT Consultant
Lunit and Daiichi Sankyo Partner to Accelerate Cancer Biomarker Discovery with AI HIT Consultant
Daiichi Sankyo (OTCMKTS:DSNKY) Trading Down 4.3% - Here's What Happened - MarketBeat
Daiichi Sankyo (OTCMKTS:DSNKY) Trading Down 4.3% - Here's What Happened MarketBeat
AstraZeneca, Daiichi Sankyo Move Enhertu to First-Line Metastatic Breast Cancer - BioSpace
AstraZeneca, Daiichi Sankyo Move Enhertu to First-Line Metastatic Breast Cancer BioSpace
Daiichi Sankyo prevails on appeal in long-running ADC patent battle with Seagen, flipping prior $...
Daiichi Sankyo prevails on appeal in long-running ADC patent battle with Seagen, flipping prior $41.8M verdict Fierce Pharma
Daiichi Sankyo (TSE:4568): Revisiting Valuation After ENHERTU’s Landmark First-Line FDA Approval ...
Daiichi Sankyo (TSE:4568): Revisiting Valuation After ENHERTU’s Landmark First-Line FDA Approval simplywall.st
Is Daiichi Sankyo (TSE:4568) Undervalued After Recent Share Price Weakness? A Fresh Look at Its 2...
Is Daiichi Sankyo (TSE:4568) Undervalued After Recent Share Price Weakness? A Fresh Look at Its 2028 Outlook Yahoo Finance
Daiichi Sankyo receives FDA untitled letter taking aim at Turalio patient ambassador video - Fier...
Daiichi Sankyo receives FDA untitled letter taking aim at Turalio patient ambassador video Fierce Pharma
Fierce Pharma Asia—Daiichi ADCs' 1st-line nod, trial deaths; Takeda's TYK2 trial win - Fierce Pharma
Fierce Pharma Asia—Daiichi ADCs' 1st-line nod, trial deaths; Takeda's TYK2 trial win Fierce Pharma
US FDA approves Daiichi Sankyo’s therapy to treat breast cancer - WKZO
US FDA approves Daiichi Sankyo’s therapy to treat breast cancer WKZO
AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment - Reuters
AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment Reuters
Daiichi Sankyo announces first patient dosed in Phase III trial of Enhertu - Clinical Trials Arena
Daiichi Sankyo announces first patient dosed in Phase III trial of Enhertu Clinical Trials Arena
Daiichi Sankyo (OTCMKTS:DSNKY) Stock Price Up 5.1% - Should You Buy? - MarketBeat
Daiichi Sankyo (OTCMKTS:DSNKY) Stock Price Up 5.1% - Should You Buy? MarketBeat
Enhertu combo cleared for use in frontline breast cancer - BioPharma Dive
Enhertu combo cleared for use in frontline breast cancer BioPharma Dive
Is Daiichi Sankyo Now an Opportunity After a 26% Share Price Slide? - Yahoo Finance
Is Daiichi Sankyo Now an Opportunity After a 26% Share Price Slide? Yahoo Finance
AstraZeneca and Daiichi’s Enhertu wins first-in-decade US oncology approval - European Pharmaceut...
AstraZeneca and Daiichi’s Enhertu wins first-in-decade US oncology approval European Pharmaceutical Review
Daiichi wins appeal of $42 million US verdict in Enhertu patent case - Reuters
Daiichi wins appeal of $42 million US verdict in Enhertu patent case Reuters
General Proximity and Daiichi Sankyo link on oncology - Pharmaceutical Technology
General Proximity and Daiichi Sankyo link on oncology Pharmaceutical Technology
U.S. FDA Clears AstraZeneca, Daiichi Sankyo Breast Cancer Drug - marketscreener.com
U.S. FDA Clears AstraZeneca, Daiichi Sankyo Breast Cancer Drug marketscreener.com
How Daiichi Sankyo modernized drug discovery using AWS Parallel Computing Service - Amazon Web Se...
How Daiichi Sankyo modernized drug discovery using AWS Parallel Computing Service Amazon Web Services (AWS)
Daiichi Sankyo’s Dr Michael Zaiac on moving beyond ‘sick care’ - EMJ
Daiichi Sankyo’s Dr Michael Zaiac on moving beyond ‘sick care’ EMJ
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next. - ...
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next. BioPharma Dive
Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd - BioSpace
Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd BioSpace
Daiichi Sankyo avoids payout in long-running patent dispute with Pfizer’s Seagen - Endpoints News
Daiichi Sankyo avoids payout in long-running patent dispute with Pfizer’s Seagen Endpoints News
General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advanc...
TROPION-Lung17: New Phase III Lung Cancer Trial Adds Medium-Term Upside Potential for AstraZeneca...
BioMed X and Daiichi Sankyo Launch Immuno-Oncology Research Team - Contract Pharma
BioMed X and Daiichi Sankyo Launch Immuno-Oncology Research Team Contract Pharma
AstraZeneca (AZN) and Daiichi Sankyo's Enhertu Combo Gains FDA A - GuruFocus
AstraZeneca (AZN) and Daiichi Sankyo's Enhertu Combo Gains FDA A GuruFocus
Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates ...
Transcript : Daiichi Sankyo Company, Limited, Q2 2026 Earnings Call, Oct 31, 2025 - marketscreene...
Transcript : Daiichi Sankyo Company, Limited, Q2 2026 Earnings Call, Oct 31, 2025 marketscreener.com
Merck and Daiichi Sankyo’s I-DXd Earns FDA Breakthrough Therapy Status in Small Cell Lung Cancer ...
Merck and Daiichi Sankyo’s I-DXd Earns FDA Breakthrough Therapy Status in Small Cell Lung Cancer BioPharm International
Daiichi Sankyo (TSE:4568) Earnings Growth Slows to 11.8%, Testing Recent Bullish Narratives - Yah...
Daiichi Sankyo (TSE:4568) Earnings Growth Slows to 11.8%, Testing Recent Bullish Narratives Yahoo Finance
Daiichi Sankyo launches its STING operation against cancer - pharmaphorum
Daiichi Sankyo launches its STING operation against cancer pharmaphorum
Daiichi Sankyo: Pressing The ADC Case Further, Not Being Felt By The Market - Seeking Alpha
Daiichi Sankyo: Pressing The ADC Case Further, Not Being Felt By The Market Seeking Alpha
Daiichi Sankyo is leveraging Azure OpenAI Service to develop generative AI and foster an AI-frien...
FDA to priority-review Daiichi Sankyo and AZ’s Enhertu sBLA - Pharmaceutical Technology
FDA to priority-review Daiichi Sankyo and AZ’s Enhertu sBLA Pharmaceutical Technology
Japan’s Daiichi Sankyo Shares Drop After Discounted Block Trades - Bloomberg.com
Japan’s Daiichi Sankyo Shares Drop After Discounted Block Trades Bloomberg.com
Stock Pitch: Daiichi Sankyo (TSE: 4568) - Morningstar Canada
Stock Pitch: Daiichi Sankyo (TSE: 4568) Morningstar Canada
Is There Now an Opportunity in Daiichi Sankyo After the Recent Share Price Slump? - simplywall.st
Is There Now an Opportunity in Daiichi Sankyo After the Recent Share Price Slump? simplywall.st
AstraZeneca-Daiichi Sankyo Enhertu Combo wins USFDA approval for 1st-line HER2-Positive Metastati...
AstraZeneca-Daiichi Sankyo Enhertu Combo wins USFDA approval for 1st-line HER2-Positive Metastatic Breast ... Medical Dialogues
What Recent Oncology Deal Means for Daiichi Sankyo Shares in 2025 - Yahoo Finance
What Recent Oncology Deal Means for Daiichi Sankyo Shares in 2025 Yahoo Finance
Wayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for...
Daiichi Sankyo (TSE:4568): Exploring Valuation as Investor Attention Grows - Yahoo Finance
Daiichi Sankyo (TSE:4568): Exploring Valuation as Investor Attention Grows Yahoo Finance
Daiichi Sankyo Establishes Third Research Institute in San Diego - Business Wire
Daiichi Sankyo Establishes Third Research Institute in San Diego Business Wire
Daiichi Sankyo (TSE:4568): Evaluating Valuation as Investor Sentiment Remains Subdued - simplywal...
Daiichi Sankyo (TSE:4568): Evaluating Valuation as Investor Sentiment Remains Subdued simplywall.st
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lower...
AstraZeneca and Daiichi Sankyo's enhertu gets US cancer approval - marketscreener.com
AstraZeneca and Daiichi Sankyo's enhertu gets US cancer approval marketscreener.com
AstraZeneca, Daiichi Sankyo's breast cancer drug gets new FDA nod - Nikkei Asia
AstraZeneca, Daiichi Sankyo's breast cancer drug gets new FDA nod Nikkei Asia
Daiichi Sankyo’s Breast Cancer Treatment, Enhertu, Approved in Japan - BioPharm International
Daiichi Sankyo’s Breast Cancer Treatment, Enhertu, Approved in Japan BioPharm International
AstraZeneca and Daiichi Sankyo's Enhertu approved as first-line therapy for HER2+ breast cancer -...
AstraZeneca and Daiichi Sankyo's Enhertu approved as first-line therapy for HER2+ breast cancer marketscreener.com
Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast C...
Merck (MRK) And Daiichi Sankyo's R-DXd Receives FDA Breakthrough Therapy Designation - Yahoo Finance
Merck (MRK) And Daiichi Sankyo's R-DXd Receives FDA Breakthrough Therapy Designation Yahoo Finance
AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy ...
AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy Yahoo Finance
AstraZeneca, Daiichi Sankyo's Enhertu Regimen Greenlit as First-line Breast Cancer Treatment in U...
AstraZeneca, Daiichi Sankyo's Enhertu Regimen Greenlit as First-line Breast Cancer Treatment in US marketscreener.com
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute betwe...
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen Business Wire
Daiichi Sankyo Breast Cancer Trial Success Boosts Investor Confidence - Meyka
Daiichi Sankyo Breast Cancer Trial Success Boosts Investor Confidence Meyka
AstraZeneca and Daiichi Sankyo Share Positive Data From Phase III DESTINY-Breast09 Trial of Enher...
AstraZeneca and Daiichi Sankyo Share Positive Data From Phase III DESTINY-Breast09 Trial of Enhertu Plus Pertuzumab Applied Clinical Trials
Daiichi Sankyo and Merck Pull Back Patritumab Deruxtecan BLA Based on Phase III HERTHENA-Lung02 O...
Daiichi Sankyo and Merck Pull Back Patritumab Deruxtecan BLA Based on Phase III HERTHENA-Lung02 Outcomes Applied Clinical Trials
AstraZeneca, Daiichi Sankyo's Enhertu Combination Gets US Approval for Breast Cancer Treatment - ...
AstraZeneca, Daiichi Sankyo's Enhertu Combination Gets US Approval for Breast Cancer Treatment marketscreener.com
AstraZeneca and Daiichi Sankyo's Datroway improves OS in TNBC - The Pharma Letter
AstraZeneca and Daiichi Sankyo's Datroway improves OS in TNBC The Pharma Letter
Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings - B...
Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings BioSpace
Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch' - Fierce P...
Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch' Fierce Pharma
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ...
AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics - Pharmafile
AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics Pharmafile
Earnings call transcript: Daiichi Sankyo Q2 2025 misses EPS forecast, stock drops - Investing.com
Earnings call transcript: Daiichi Sankyo Q2 2025 misses EPS forecast, stock drops Investing.com
AstraZeneca and Daiichi Sankyo Bolster Case For Enhertu In Early Breast Cancer - Citeline News & ...
AstraZeneca and Daiichi Sankyo Bolster Case For Enhertu In Early Breast Cancer Citeline News & Insights
Daiichi Sankyo connects cherry blossom trees to future of oncology pipeline - Medical Marketing a...
Daiichi Sankyo connects cherry blossom trees to future of oncology pipeline Medical Marketing and Media
Daiichi Sankyo Q2 2025 slides: Revenue growth overshadowed by profit decline - Investing.com
Daiichi Sankyo Q2 2025 slides: Revenue growth overshadowed by profit decline Investing.com
AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data - BioSpace
AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data BioSpace
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lower...
Daiichi Sankyo celebrates its roots and blooming future at DC cherry blossom festival - Fierce Ph...
Daiichi Sankyo celebrates its roots and blooming future at DC cherry blossom festival Fierce Pharma
Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to A...
How Breakthrough ESMO 2025 Oncology Data at Daiichi Sankyo (TSE:4568) Has Changed Its Investment ...
How Breakthrough ESMO 2025 Oncology Data at Daiichi Sankyo (TSE:4568) Has Changed Its Investment Story Yahoo Finance
Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥39.00 - simplywall.st
Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥39.00 simplywall.st
Merck and Daiichi Sankyo Launch Global Phase III Trial of Novel Antibody Drug Conjugate in Advanc...
Merck and Daiichi Sankyo Launch Global Phase III Trial of Novel Antibody Drug Conjugate in Advanced Esophageal Squamous Cell Carcinoma Applied Clinical Trials
AAX Biotech Announces Collaboration with Daiichi Sankyo to Evaluate Opti-mAb® Technology in Next-...
Daiichi Sankyo (DSKYF) Reports Strong 1H Financial Results - GuruFocus
Daiichi Sankyo (DSKYF) Reports Strong 1H Financial Results GuruFocus
AstraZeneca and Daiichi Sankyo Treatment Wins First of Its Kind FDA Blessing to Treat Lung Cancer...
AstraZeneca and Daiichi Sankyo Treatment Wins First of Its Kind FDA Blessing to Treat Lung Cancer The Daily Upside
Immuto Scientific Announces $8M Seed 2 Financing and Daiichi Sankyo Collaboration to Uncover a Ne...
Earnings call transcript: Daiichi Sankyo’s Q4 2025 results show strong growth - Investing.com
Earnings call transcript: Daiichi Sankyo’s Q4 2025 results show strong growth Investing.com
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-...
AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study - Seeking Alpha
AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study Seeking Alpha
Weekly Trades: Why analysts recommend Daiichi Sankyo Company Limited (D4S) stock - Portfolio Retu...
AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy - ...
AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy MedCity News
Daiichi Sankyo - drugdiscoverytrends.com
Daiichi Sankyo drugdiscoverytrends.com
AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer - PM...
AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer PMLiVE
Sankyo Co. Updates on Share Repurchase Program - TipRanks